Characterization of vitamin D insensitive prostate cancer cells

The antitumor effects of 1,25-dihydroxyvitamin D3 (calcitriol) are being exploited for prevention and treatment of prostate cancer (CaP). These studies examined antitumor effects of calcitriol in primary cell cultures derived from transgenic adenocarcinoma of mouse prostate (TRAMP) mice chronically treated with calcitriol (20μg/kg) or vehicle 3x/week (MWF) from 4 weeks-of-age until palpable tumors developed. This is a report on the response of 2 representative control (vitamin D naive, naive) and calcitriol-treated (vitamin D insensitive, VDI) cells to calcitriol. VDI cells were less sensitive to calcitriol based on less cell growth inhibition and less inhibition of DNA synthesis as measured by MTT and BrdU incorporation assays. Similarly, VDI cells were also less sensitive to growth inhibition by the vitamin analog, 19-nor-1α,25-dihydroxyvitamin D2 (paricalcitol). There was no change in apoptosis following treatment of naive and VDI cells with calcitriol. Vitamin D receptor (VDR) expression was up-regulated by calcitriol in both naive and VDI cells. Calcitriol induced the vitamin D metabolizing enzyme, 24-hydroxylase (cyp24) mRNA and enzyme activity similarly in naive and VDI cells as measured by RT-PCR and HPLC respectively. In summary, VDI cells are less responsive to the antiproliferative effects of calcitriol. Understanding vitamin D insensitivity will further clinical development of vitamin D compounds for prevention and treatment of CaP.